Follicular lymphoma, a sub-type of indolent B cell non-Hodgkin lymphoma (NHL), accounts for approximately 20% of the total NHL cases. On average, each year, 15,000 new Follicular lymphoma cases are diagnosed in the US alone. In 2020 there were 35,737 prevalent cases of Follicular lymphoma in the 7MM, out of which the highest cases were in the United States.
As per DelveInsight analysis, in 2020, the Follicular Lymphoma market revenue was estimated to be USD 1,451 million in the 7MM (i.e the USA, EU5, and Japan), which is anticipated to increase further by 2030. Among the 7MM, the USA accounted for approximately 54% of the total market share, depicting a promising future outlook.
Some of the key companies in the segment diligently working to overcome the therapeutics challenges with their pipeline products include Incyte, Bristol Myers Squibb, Nordic Nanovector ASA, ADC Therapeutics, MorphoSys, Regeneron, Novartis, MEI Pharma, BeiGene, Xynomic Pharma, TG Therapeutics, Inc., Roche, Takeda, and several others.
For more details, visit: Follicular Lymphoma Therapeutics Market